Great Lakes Advisors LLC Invests $812,000 in Stryker Corporation $SYK

Great Lakes Advisors LLC acquired a new stake in Stryker Corporation (NYSE:SYK) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 2,579 shares of the medical technology company’s stock, valued at approximately $812,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Varma Mutual Pension Insurance Co grew its position in shares of Stryker by 10.5% during the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after buying an additional 5,100 shares during the period. QRG Capital Management Inc. raised its position in shares of Stryker by 7.4% in the 4th quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock valued at $21,281,000 after acquiring an additional 4,186 shares during the period. Swedbank AB boosted its stake in Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after acquiring an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in Stryker by 31.1% during the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock worth $9,426,000 after acquiring an additional 6,367 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in Stryker by 6.5% during the first quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares during the period. 77.09% of the stock is owned by institutional investors.

Stryker Price Performance

SYK stock opened at $329.86 on Friday. The stock has a 50-day moving average price of $326.99 and a two-hundred day moving average price of $332.64. The stock has a market cap of $126.52 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 665,370 shares of company stock valued at $216,238,501 in the last quarter. 4.60% of the stock is currently owned by insiders.

Stryker News Roundup

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Analysts Set New Price Targets

Several equities research analysts have weighed in on SYK shares. Robert W. Baird set a $385.00 target price on shares of Stryker in a report on Friday, May 1st. Citizens Jmp decreased their price target on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a report on Monday, August 3rd. Sanford C. Bernstein set a $410.00 price objective on shares of Stryker in a research report on Friday, May 1st. Needham & Company LLC dropped their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, BMO Capital Markets began coverage on Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.